Zentalis Pharmaceuticals (ZNTL) Competitors

Rezolute (NASDAQ:RZLT) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, community ranking, risk and institutional ownership.

Which has better earnings and valuation, RZLT or ZNTL?

Rezolute has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Rezolute is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$68.46M	-$1.15	-3.76
Zentalis Pharmaceuticals	$26.87M	3.93	-$292.19M	-$3.13	-0.47

Which has more volatility & risk, RZLT or ZNTL?

Rezolute has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Does the media refer more to RZLT or ZNTL?

In the previous week, Rezolute had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 3 mentions for Rezolute and 2 mentions for Zentalis Pharmaceuticals. Rezolute's average media sentiment score of 1.84 beat Zentalis Pharmaceuticals' score of 1.81 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is RZLT or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -43.91% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-70.27%	-62.41%
Zentalis Pharmaceuticals	N/A	-43.91%	-34.96%

Does the MarketBeat Community prefer RZLT or ZNTL?

Rezolute received 11 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. Likewise, 79.57% of users gave Rezolute an outperform vote while only 61.76% of users gave Zentalis Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Rezolute	Outperform Votes 74 79.57%	Underperform Votes 19 20.43%
Zentalis Pharmaceuticals	Outperform Votes 63 61.76%	Underperform Votes 39 38.24%

Do analysts recommend RZLT or ZNTL?

Rezolute currently has a consensus price target of $11.83, indicating a potential upside of 173.92%. Zentalis Pharmaceuticals has a consensus price target of $8.24, indicating a potential upside of 461.19%. Given Zentalis Pharmaceuticals' higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Zentalis Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44

Do institutionals and insiders hold more shares of RZLT or ZNTL?

83.0% of Rezolute shares are owned by institutional investors. 18.4% of Rezolute shares are owned by company insiders. Comparatively, 1.9% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Rezolute beats Zentalis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.